LGND Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Company profile
Ticker
LGND
Exchange
Website
CEO
John Higgins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LIGAND PHARMACEUTICALS
SEC CIK
Corporate docs
IRS number
770160744
LGND stock data
()
News
Here Are The Stocks With The Highest Short Interest Rate
25 Feb 21
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
11 Feb 21
Stocks That Hit 52-Week Highs On Wednesday
10 Feb 21
Top 30 High Short Interest Stocks As Of Wednesday, Feb. 10, 2021 (Via HighShortInterest.com)
10 Feb 21
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
10 Feb 21
Press releases
Final Results for the year ended 31 December 2020
1 Apr 21
4D Pharma Appointments Paul Maier to the Board as Non-Executive Director
1 Mar 21
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
3 Feb 21
Ligand Pharmaceuticals, Inc. to Host Earnings Call
3 Feb 21
Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
2 Feb 21
Investment data
Securities sold
Number of investors
Calendar
23 Feb 21
11 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 47.96M | 47.96M | 47.96M | 47.96M | 47.96M | 47.96M |
Cash burn (monthly) | 136.38M | 2.03M | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | 460.19M | 6.84M | n/a | n/a | n/a | n/a |
Cash remaining | -412.23M | 41.13M | n/a | n/a | n/a | n/a |
Runway (months of cash) | -3.0 | 20.3 | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Feb 21 | Kozarich John W | Common Stock | Option exercise | Aquire M | No | No | 10.12 | 2,500 | 25.3K | 29,708 |
22 Feb 21 | Kozarich John W | NQSO Common Stock | Option exercise | Dispose M | No | No | 10.12 | 2,500 | 25.3K | 4,835 |
15 Feb 21 | Korenberg Matthew E | Common Stock | Payment of exercise | Dispose F | No | No | 172.46 | 969 | 167.11K | 39,443 |
15 Feb 21 | Korenberg Matthew E | Common Stock | Payment of exercise | Dispose F | No | No | 172.46 | 906 | 156.25K | 40,412 |
15 Feb 21 | Korenberg Matthew E | Common Stock | Payment of exercise | Dispose F | No | No | 172.46 | 434 | 74.85K | 41,318 |
15 Feb 21 | Higgins John L | Common Stock | Payment of exercise | Dispose F | No | No | 172.46 | 2,061 | 355.44K | 337,848 |
15 Feb 21 | Higgins John L | Common Stock | Payment of exercise | Dispose F | No | No | 172.46 | 1,947 | 335.78K | 339,909 |
15 Feb 21 | Higgins John L | Common Stock | Payment of exercise | Dispose F | No | No | 172.46 | 1,204 | 207.64K | 341,856 |
15 Feb 21 | Berkman Charles S | Common Stock | Payment of exercise | Dispose F | No | No | 172.46 | 442 | 76.23K | 27,891 |
15 Feb 21 | Berkman Charles S | Common Stock | Payment of exercise | Dispose F | No | No | 172.46 | 368 | 63.47K | 28,333 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 233 |
Opened positions | 29 |
Closed positions | 44 |
Increased positions | 80 |
Reduced positions | 89 |
13F shares |
Current |
---|---|
Total value | 2.29B |
Total shares | 22.7M |
Total puts | 793.5K |
Total calls | 281.6K |
Total put/call ratio | 2.8 |
Largest owners |
Shares | Value |
---|---|---|
William Blair Investment Management | 2.04M | $202.98M |
BLK Blackrock | 1.97M | $195.52M |
JHG Janus Henderson | 1.61M | $160.35M |
Vanguard | 1.46M | $145.09M |
Wasatch Advisors | 1.17M | $116.26M |
STT State Street | 1.17M | $115.9M |
Cardinal Capital Management | 1.09M | $108.23M |
MCQEF Macquarie | 894.68K | $88.98M |
Conestoga Capital Advisors | 716.44K | $71.25M |
Villere ST Denis J & Co | 642.07K | $63.85M |
Financial report summary
?Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AbCellera, abemaciclib, Accent, acid, Adalvo, Adept, affinity, AI, alfa, alia, allegedly, alliance, altogether, Alvogen, amide, AML, annex, appoint, appointed, Arabia, ASCEND, Asia, Asian, asparaginase, bacterium, batoclimab, Bayer, behavior, Beloteca, benchmark, BI, binding, bintrafusp, bioactivity, BLA, Bonsity, Bonteo, Brian, Buyer, Caldera, career, Carolina, carrier, CDK, CF, CFTR, chicken, choice, chose, chosen, Cipla, CNS, commonly, conjugate, conjugated, consortium, constitute, constituted, contact, correlate, cow, customizable, deep, delinquency, denied, denying, deprioritizing, diphtheria, discern, discrimination, discriminatory, distancing, Distinguished, doctrine, Dr, DUPLEX, durability, Durham, duty, earnout, EC, ELAINE, emerge, epidemic, EQRx, Erwinia, escalation, Eton, evolve, expert, feedback, fiduciary, fight, fisogatinib, flat, FORTEO, forum, founder, FPRE, fraudulently, Gavi, GE, GEM, gene, Genekey, globe, grow, growing, harassment, heat, Higuchi, HitGen, hospital, hospitalization, hotline, hydrolase, IgG, imposed, inapplicable, incentivizing, induced, Inst, Intelligence, interval, intramuscular, invasive, IP, irbesartan, Jazz, joint, Kangchen, kind, lab, leader, licensure, lifespan, linked, Livogiva, longest, loyalty, LTPTM, luminespib, Lundstrom, lymphoblastic, magnitude, Mainland, Malaysia, markedly, marker, MDS, MENA, meningococcal, micro, microbial, microcapillary, Minotaur, missed, molecular, morbidity, mutant, mutation, NaN, Neuritek, neurodegenerative, neurological, nonclinical, nonsense, nontransferable, NSCLC, obstructive, OmniTaur, OnKure, optica, ORR, output, outsourced, pain, paired, pandemic, Pandion, Pat, pathway, pause, peak, pegaspargase, Pelican, percent, Pfenex, pharmacodynamic, Phoenix, pMDI, pneumococcal, Pneumosil, posed, pre, premature, Prequalification, prevalent, Professor, prophylactic, protocol, proud, PTAB, pulmonary, rat, readthrough, recommended, redirecting, refusal, regorafenib, remission, reopening, retention, retirement, RHHBY, Roche, role, ROW, RTOR, RubrYc, salary, Saudi, SC, scalable, SCS, secondary, sensitive, sequencing, Serum, sexual, shock, SII, silico, Singapore, slightly, Smider, solubilize, spread, stack, staffing, Stanford, Stella, strive, subsidized, substance, sugemalimab, suggest, suitable, superior, suppression, Taiho, teclistamab, teriparatide, territory, Thailand, thereunder, thousand, toxin, tradename, transformative, transmembrane, travel, Travere, truncated, tuition, unresectable, unvested, usage, vaccine, Valentino, VALOR, Vaughn, Veklury, versatility, vivo, VOYAGE, waived, welfare, Wistar, withheld, xPloration, XRPro, zimberelimab
Removed:
accumulation, ADHF, antibiotic, assured, averaged, avian, bioavailability, BMS, calculating, Capitsol, clarified, classification, combining, death, delafloxacin, Department, DUET, expiring, faster, fluoroquinolone, improving, inflammation, instrument, interpretation, interpretative, invoice, Journal, lived, maximize, MRSA, nondeductible, notably, principle, repertoire, revision, space, survival, uncollectible, Washington, week, wholly, wrong
Financial reports
10-K
2020 FY
Annual report
23 Feb 21
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
8 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
Current reports
8-K
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
3 Feb 21
8-K
Entry into a Material Definitive Agreement
28 Jan 21
8-K
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
21 Dec 20
8-K
Departure of Directors or Certain Officers
16 Dec 20
8-K/A
Financial Statements and Exhibits
10 Dec 20
8-K
Other Events
2 Dec 20
8-K
Other Events
23 Nov 20
8-K
Amendments to Articles of Incorporation or Bylaws
30 Oct 20
8-K
Ligand Reports Third Quarter 2020 Financial Results
30 Oct 20
8-K
Results of Operations and Financial Condition
20 Oct 20
Registration and prospectus
S-8
Registration of securities for employees
27 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
30 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
16 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
11 Sep 20
SC TO-T
Third party tender offer statement
31 Aug 20
SC TO-C
Information about tender offer
10 Aug 20
SC TO-C
Information about tender offer
10 Aug 20
S-8
Registration of securities for employees
8 Aug 19
S-8
Registration of securities for employees
28 Jul 16
D
$85.44M in equity, sold $85.44M, 22 investors
24 Jan 16
Proxies
DEF 14A
Definitive proxy
12 Nov 20
PRE 14A
Preliminary proxy
30 Oct 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
DEFA14A
Additional proxy soliciting materials
4 Jun 19
DEF 14A
Definitive proxy
23 Apr 19
DEFA14A
Additional proxy soliciting materials
23 Apr 19
DEFA14A
Additional proxy soliciting materials
3 Jun 18
PRER14A
Preliminary revised proxy
22 May 18
DEFA14A
Additional proxy soliciting materials
30 Apr 18
Other
UPLOAD
Letter from SEC
12 Jan 21
CORRESP
Correspondence with SEC
5 Jan 21
UPLOAD
Letter from SEC
22 Dec 20
CORRESP
Correspondence with SEC
15 Sep 20
CT ORDER
Confidential treatment order
15 Jun 20
CT ORDER
Confidential treatment order
23 Aug 18
CT ORDER
Confidential treatment order
22 May 18
CT ORDER
Confidential treatment order
2 Apr 18
UPLOAD
Letter from SEC
6 Feb 18
CORRESP
Correspondence with SEC
16 Jan 18
Ownership
4
LIGAND PHARMACEUTICALS / JOHN W KOZARICH ownership change
23 Feb 21
4
LIGAND PHARMACEUTICALS / Charles S Berkman ownership change
18 Feb 21
4
LIGAND PHARMACEUTICALS / MATTHEW W FOEHR ownership change
18 Feb 21
4
LIGAND PHARMACEUTICALS / JOHN L HIGGINS ownership change
18 Feb 21
4
LIGAND PHARMACEUTICALS / Matthew E Korenberg ownership change
18 Feb 21
SC 13G/A
LIGAND PHARMACEUTICALS / CARDINAL CAPITAL MANAGEMENT ownership change
16 Feb 21
SC 13G
LIGAND PHARMACEUTICALS / STATE STREET ownership change
16 Feb 21
4
LIGAND PHARMACEUTICALS / Todd C Davis ownership change
12 Feb 21
SC 13G
LIGAND PHARMACEUTICALS / MACQUARIE ownership change
12 Feb 21
SC 13G/A
LIGAND PHARMACEUTICALS / JANUS HENDERSON ownership change
11 Feb 21
Patents
GRANT
Utility
Method for analysis using X-ray fluorescence
16 Mar 21
The present invention is a method to quantify biomarkers.
APP
Utility
Methods and Compositions Associated with the Granulocyte Colony-stimulating Factor Receptor
18 Feb 21
Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR).
APP
Utility
Imidazo-fused Heterocycles and Uses Thereof
11 Feb 21
Compounds and methods in the fields of chemistry and medicine are disclosed.
GRANT
Utility
1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors
12 Jan 21
Inventors: Stephen Stokes, Christopher John Graham, Stuart Christopher Ray, Emma Jayne Stefaniak
GRANT
Utility
Methods and compositions for modulating hormone levels
28 Dec 20
Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.
Transcripts
2020 Q4
Earnings call transcript
3 Feb 21
2020 Q3
Earnings call transcript
30 Oct 20
2020 Q2
Earnings call transcript
3 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q3
Earnings call transcript
5 Nov 19
2019 Q2
Earnings call transcript
30 Jul 19
2019 Q1
Earnings call transcript
2 May 19
2018 Q4
Earnings call transcript
8 Feb 19
2018 Q3
Earnings call transcript
8 Nov 18
2018 Q2
Earnings call transcript
6 Aug 18
Reddit threads
Daily Discussion Thread for March 02, 2021
2 Mar 21
Don’t feel so bad. This loss wiped out my GME gains completely. Holding.
21 Feb 21
Wall Street Week Ahead for the trading week beginning February 15th, 2021
13 Feb 21
As requested, here's a visualization of which stocks are being talked about the most by WSB newcomers vs. 'OGs'
11 Feb 21
Motley fool picking up $LGND - Great Earnings Report and recent excellent analyst rating
9 Feb 21
Here's a summary of WSB discussion in January. "Promoter Ratio" is a new metric I'm using to track where discussion comes from. Higher values indicate a tighter, more active group of users talking about a given ticker.
7 Feb 21
Just Hold A Little Longer Man
5 Feb 21
r/wallstreetbets has been infiltrated, u/zjz removed, now shadowbans and censoring posts
4 Feb 21
GME POV: someone who already exited position
3 Feb 21
They all follow $ GME.
3 Feb 21